New Parkinson’s Cell Therapy Research: What Patients Should Know
Quick Summary TreeFrog Therapeutics announced preclinical data for TFG‑001, a 3D neural microtissue therapy for Parkinson’s disease. The approach aims to replace damaged dopamine‑producing neurons. Preclinical models showed rapid dopamine release, nerve regrowth, and motor recovery. However, the work is still preclinical; a Clinical Trial Application is expected in 2027.
June 1, 2026
No Comments
